Mastalgia: a review of management.

Abstract

Mastalgia affects up to two-thirds of women at some time during their reproductive lives. It is usually benign, but thefear of underlying breast cancer is why many women present for evaluation. Mastalgia can be associated with premenstrual syndrome, fibrocystic breast disease, psychologic disturbance and, rarely, breast cancer. Occasionally, extramammary conditions, like Tietzie syndrome, present as mastalgia. A thorough clinical evaluation is required to assess the cause. The majority of women can be reassured after a clinical evaluation. Approximately 15% require pain-relieving therapy. Mechanical breast support; a low-fat, high-carbohydrate diet; and topical nonsteroidal antiinflammatory agents are reasonable first-line treatments. Hormonal agents, such as bromocriptine, tamoxifen and danazol, have all demonstrated efficacy in the treatment of mastalgia. Side effects, however, limit their extensive use. Danazol is the only FDA-approved hormonal treatment and is best used in cyclic form to limit the adverse effects. Lisuride maleate is a new agent recently studied for the treatment of mastalgia. Initial data on this medication are encouraging. Sixty percent of cyclic mastalgia recurs after treatment. Noncyclic mastalgia responds poorly to treatment but resolves spontaneously in up to 50% of cases.

• Authors: Alexander Olawaiye, Matthew Withiam-Leitch, George Danakas, Kenneth Kahn
• Journal: The Journal of reproductive medicine (J Reprod Med) Vol. 50 Issue 12 Pg. 933-9 (Dec 2005) ISSN: 0024-7758 [Print] United States
• PMID: 16444894 (Publication Type: Journal Article, Review)

Topics

• Affective Symptoms (complications)
• Breast Diseases (epidemiology, etiology, therapy)
• Breast Neoplasms (complications)
• Female
• Fibrocystic Breast Disease (complications)
• Humans
• Pain (epidemiology, etiology)
• Pain Management
• Premenstrual Syndrome (complications)
• Prevalence
• Risk Factors